CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.99BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
121.95%vs all stocks
Market Capitalization
1.99BUSDvs all stocks (USD)
Enterprise Value
1.76BUSDvs all stocks (USD)
Forward P/E
-18.43xvs Biotechnology peers
Price to Book (MRQ)
9.17xvs Biotechnology peers
Enterprise to EBITDA
-49.96xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.05%vs Biotechnology peers
Return on Equity (TTM)
-46.63%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-61.70MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-36.51MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-38.60MUSDvs all stocks (USD)
Pre-tax Income
-41.72MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-41.72MUSDFY2025 · Dec 31, 2025EBIT
-35.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-35.28MUSDFY2025 · Dec 31, 2025Research & Development
22.84MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.76MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.59MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.82MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.71USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.71USDFY2025 · Dec 31, 2025Basic Shares Outstanding
11.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.72MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-25.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
57.98MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.72MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.49MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.26MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.42MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.42MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.40MSharesUpdated Sep 28, 2026Float Shares
10.68MSharesUpdated Sep 28, 2026Shares Short
2.33MSharesUpdated Sep 28, 2026Short Ratio
11.81daysvs all stocks
Short % of Shares Outstanding
18.26%vs all stocks
% Held by Insiders
11.59%vs all stocks
% Held by Institutions
104.76%vs all stocks
Total Cash (MRQ)
250.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
17.39USDUpdated Sep 28, 2026Total Debt (MRQ)
22.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1044xvs Biotechnology peers
Current Ratio (MRQ)
21.18xvs Biotechnology peers
Book Value per Share (MRQ)
15.06USDUpdated Sep 28, 2026Total Assets
59.56MUSDvs all stocks (USD)
Total Current Assets
58.99MUSDFY2025 · Dec 31, 2025Total Liabilities
31.58MUSDFY2025 · Dec 31, 2025Total Non-current Assets
572.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.23MUSDFY2025 · Dec 31, 2025Total Current Liabilities
11.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
57.98MUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
4.59MUSDFY2025 · Dec 31, 2025Short-term Debt
202.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.90MUSDFY2025 · Dec 31, 2025Long-term Debt
431.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
17.76MUSDFY2025 · Dec 31, 2025Common Stock (Book)
12.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-135.45MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
27.98MUSDvs all stocks (USD)
52-Week Low
59.16USDUpdated Sep 28, 202652-Week High
161.38USDUpdated Sep 28, 202652-Week Change
121.95%vs all stocks
50-Day MA
149.29USDUpdated Sep 28, 2026200-Day MA
122.75USDUpdated Sep 28, 2026Avg 10-Day Volume
239.91KSharesUpdated Sep 28, 2026Avg 30-Day Volume
206.85KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-4.85USDUpdated Sep 28, 2026Other Income / Expense
115.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Market cap is $1.99B, above the global median of $1.18BNotable
Market cap (USD): 1,990,665,511Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mesoblast Limited
Tier 1ProductionApproval-Gated PipelineRule
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule